Satellos Gets FDA Clearance to Test Forazapadin in FSHD, Secures $5M Non-Dilutive Funding
MSLE sits 64% above its 52-week low of $5.44.
Summary
FDA cleared Satellos' IND for forazapadin in FSHD, its second indication, and the FSHD Canada Foundation will provide up to US$5 million in non-dilutive funding. A Phase 2 FSHD study is planned for Q4 2026.
Key Events · Product Development and Regulatory · MSLE
-
FDA Clears IND for FSHD
FDA cleared the Investigational New Drug application for forazapadin in facioscapulohumeral muscular dystrophy (FSHD), the second indication for the drug candidate.
-
Non-Dilutive Financing Secured
FSHD Canada Foundation will provide up to US$5 million in milestone payments over five quarters in exchange for a capped revenue-sharing interest in future FSHD-related proceeds.
-
Phase 2 Study Planned for Q4 2026
A randomized, double-blind, placebo-controlled Phase 2 study will evaluate 60 mg and 120 mg doses of forazapadin in adults with FSHD, with initiation expected in Q4 2026.
-
Expands Muscle Regeneration Franchise
Forazapadin is already in Phase 2 trials for Duchenne muscular dystrophy (DMD); this FSHD clearance broadens the company's pipeline into a second degenerative muscle disease with no approved therapies.
Analysis · MSLE · Life Sciences
Satellos expands its lead drug candidate into a second muscular dystrophy indication with FDA clearance of its IND for FSHD, a disease with no approved therapies affecting an estimated 800,000 people worldwide. The company also secured up to US$5 million in non-dilutive financing from the FSHD Canada Foundation, extending its cash runway without shareholder dilution. A Phase 2 proof-of-concept study is expected to start in Q4 2026, testing two dose levels of forazapadin. This builds on positive interim DMD data reported in July and positions the company to pursue a broader muscle-regeneration franchise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MSLE was trading at $8.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178.4M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.